Analysts Expect InspireMD, Inc. (NSPR) to Post ($2.50) EPS

Shares of InspireMD, Inc. (NASDAQ:NSPR) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Analysts have set a 1 year consensus target price of $15.00 for the company and are predicting that the company will post ($2.50) EPS for the current quarter, according to Zacks. Zacks has also assigned InspireMD an industry rank of 101 out of 255 based on the ratings given to related companies.

Separately, HC Wainwright reissued a “buy” rating on shares of InspireMD in a report on Wednesday, March 13th.

Shares of NASDAQ:NSPR traded down $2.99 during mid-day trading on Friday, reaching $4.15. The stock had a trading volume of 332,971 shares, compared to its average volume of 46,192. InspireMD has a twelve month low of $5.51 and a twelve month high of $82.00.

InspireMD (NASDAQ:NSPR) last posted its earnings results on Tuesday, February 19th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.82 million during the quarter.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Featured Story: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on InspireMD (NSPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.